Immune Response Biopharma, Inc. (c) 2010-2020


Press Releases TM

Immune Response BioPharma, Inc. Update Expects NeuroVax & Remune Expanded Access To be Oversubscribed Right to Try Enrollment Picking up Steam: Robust Patients may only enroll via Immune Response Website: IRBP changes compensation to unlimited income per patient per injection no cap: patient will receive vaccine and payment for 500 patients enrolled once study enrollment reached no additional patients will be allowed to participate due to low supply of vaccine

April 23rd 2019

Immune Response BioPharma, Inc. Business Update NeuroVax General Availability for Clinical Use & Right to Try Target Q4 2019 - Q1 2020, Remune HIV Vaccine Target Q4 2019 - Q1 2020; IRBP Transitions to Two Vial Kit of Antigen & Adjuvant with Syringe Ready to Inject for Both Remune & NeuroVax in lieu of single pre-filled syringes improving quality and shelf life.

February 15th 2019

Immune Response BioPharma, Inc. Bringing Significantly Lower HIV & MS Drug/Vaccine Treatment Costs with Blockbuster HIV & MS Vaccines' Remune & NeuroVax Right to Try Launch Securing the Future for HIV & MS Patients Driving Patient Treatment Success with Novel HIV Vacccine Remune & NeuroVax MS Vaccines both First in Class & Best in Class treatments.

Sept 15th 2018on

Immune Response BioPharma, Inc. Opens Enrollment for Expanded Access Right to Try for Remune HIV Vaccine & NeuroVax MS Vaccines 500 patients: Patients Enroll via website with $1 Paypal refundable clinical services fee to reserve spot and complete forms sent via email to patients: ICF, LOA, Patients will Recieve $5000 Cash Compensation: $5M total; FDA Expanded Access Studies Protocol to be Listed on

Sept 1st 2018

Immune Response BioPharma, Inc. To Begin Enrollment of Open Recruiting for Expanded Access Studies Compassionate Use/Right to Try for NeuroVax & Remune on September 1st 2018 for first 1500 Patients First Come First Served Vaccine Made to Order Target 4-6 months manufacturing timeframe & delivery upon successful enrollment & demand: Studies on update on pending & patients will enroll on compassionate use webpage under construction starting Sept 1st 2018

July 22nd 2018 

Immune Response BioPharma, Inc. To Provide a Limited Supply of 3000 Doses of Each of HIV Vaccine Remune & MS Vaccine NeuroVax for Right to Try Use for HIV & MS Patients: IRBP Will Take Advance Orders to Meet Patient Demand on A First Come Basis at $3k per Injection, Once 3k Doses Reserved No More Vaccine Will be Provided as IRBP Lacks Capacity to Manufacture More, IRBP to Take Advance Orders on Compassionate Use Webpage Under Construction: News to Follow

June 10th 2018

Immune Response BioPharma, Inc. Applauds the Passage of the Right to Try Bill Signed into Law: IRBP will File a Large Intent to Treat Patient Population; Treatment IND Under the Current FDA Expanded Access Program

June 10th 2018

Immune Response BioPharma, Inc. Remune BLA for Adults Update Files FDA FDRR Formal Dispute Resolution Request for Arbitration of Approval for Remune, if Necessary IRBP  Warns the FDA that IRBP will Seek Relief in Federal District Court,  IRBP Confident Remune will be Approved the Easy Way or the Hard Way, IRBP to make Remune Available for Right to Try Use 

April 7th 2018

Immune Response BioPharma, Inc. Remune Pediatric BLA  Update Pending to be Filed Under Protest FDA PDFUA Date TBD TBA

April 7th 2018

Immune Response BioPharma, Inc. Applauds Passage of House Bill & Endorses Congressional Federal Right to Try Bill Legislation 

April 7th 2018








                        Immune Response BioPharma, Inc.TM Copyright (C) 2010-2020  All Rights Reserved